Percheron Therapeutics Limited
Australian Securities ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James Garner
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- L30, Collins Place Melbourne VIC Australia 3000
- IPO Date
- Dec 26, 2023
- Website
- percherontx.com
- Similar Companies
- Business
- Percheron Therapeutics Limited (ASX:PER) is an Australian biotechnology company focused on the research, development and commercialization of novel antisense oligonucleotide therapies targeting rare diseases and oncology indications. Founded in 2000 and headquartered in Melbourne, Victoria, the company leverages Ionis Pharmaceuticals' proprietary drug discovery platform to design inhibitors that bind to specific mRNA sequences, preventing protein production implicated in disease pathology; its lead product candidates include avicursen (ATL1102), an antisense inhibitor of the CD49d receptor in Phase II development for Duchenne muscular dystrophy, limb-girdle muscular dystrophy and multiple sclerosis, and atesidorsen (ATL1103), a growth hormone receptor antagonist that has completed Phase II trials for acromegaly and is under evaluation for other growth hormone-related disorders. The company operates primarily in Australia with global development ambitions, targeting unmet needs in rare pediatric diseases that have garnered US FDA orphan drug and rare pediatric designations for key programs. In December 2023, the company rebranded from Antisense Therapeutics Limited to Percheron Therapeutics Limited to reflect its expanded pipeline focus. Following a negative Phase IIb outcome for its lead program in December 2024, Percheron accelerated partnering discussions in early 2025, receiving initial proposals by February and actively pursuing strategic alliances; in June 2025, it in-licensed HMBD-002, a monoclonal antibody from Singapore-based Hummingbird Bioscience, for solid tumor applications, marking a diversification into antibody therapeutics alongside its core antisense platform. As of September 2025, the company reported A$5.7 million in cash reserves after milestone payments, supporting ongoing pipeline advancement and business development amid a lean operation with approximately eight employees.
Percheron presents ASCO data supporting HMBD-002's potential in hard-to-treat breast cancer
Small cap Watch: Biotech, gold explorers and consumer brands deliver key updates
Percheron Therapeutics secures proposed WHO drug name for HMBD-002 cancer therapy
Imugene strengthens board with biotech and pharma appointments
Percheron Therapeutics raises $2.2 million as HMBD-002 phase II preparations advance
Nova Minerals moves closer to US redomicile as shareholder vote and NYSE listing loom
Recce clears Indonesian Phase 3 site inspection as diabetic foot infection trial advances
Percheron shares phase I HMBD-002 data at AACR as it advances next stage of development
Lumos Diagnostics expands WellStreet rollout to 43 sites as FebriDx gains US traction
Hastings locks in African feedstock supply, puts Thailand rare earths plant on track for year-end cash flow
Percheron raises $2.2 million to back phase II push for HMBD-002
Astron advances Donald Project with $759m NPV BFS
Bayan Mining joins US defence consortium to target rare earths supply chain
AIC Mines grows Eloise project MRE to 31.2Mt
St George taps European rare earths expertise to advance Araxá processing strategy
Kairos to rebrand as Pilbara Gold after shareholder approval
Percheron flags ASCO nod for HMBD-002 cancer therapy data
Tamboran farms down Beetaloo acreage in US$28.5m deal with Daly Waters Energy
Active Energy deploys team to UAE as first project nears completion
Metals One secures 30% stake in South African gold venture for $1.8m